---
title: Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis
nct_id: NCT02271971
overall_status: COMPLETED
phase: NA
sponsor: Pontificia Universidad Catolica de Chile
study_type: INTERVENTIONAL
primary_condition: Psoriasis
countries: Chile
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02271971.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02271971"
ct_last_update_post_date: 2015-11-04
last_seen_at: "2026-05-12T06:34:48.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis

**Official Title:** Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Moderate to Severe Psoriasis

**NCT ID:** [NCT02271971](https://clinicaltrials.gov/study/NCT02271971)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 39
- **Lead Sponsor:** Pontificia Universidad Catolica de Chile
- **Conditions:** Psoriasis, Metabolic Syndrome, Vitamin D Deficiency
- **Start Date:** 2014-10
- **Completion Date:** 2015-10
- **CT.gov Last Update:** 2015-11-04

## Brief Summary

The purpose of this study is to determine whether supplementation with oral vitamin D (cholecalciferol) improves metabolic parameters in patients with moderate to severe psoriasis.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Clinical diagnosis of moderate to severe psoriasis.
* Being treated with methotrexate with stable doses for al least 1 month.

Exclusion Criteria:

* Phototherapy within the past 2 months.
* History of psoriatic arthritis, rheumatoid arthritis, type 1 diabetes mellitus or inflammatory bowel disease.
* Use of vitamin d supplements or fish oil supplements in the past 2 months.
* Use of hypolipidemic drugs, hypoglycemic drugs, glucose sensitizers, oral corticosteroids, orlistat, cholestyramine, phenobarbital or phenytoin within the past 2 months.
* Pregnancy or lactation.
```

## Arms

- **Vitamin D3 supplementation** (EXPERIMENTAL) — Subjects in the experimental arm will receive a daily 5.000 IU vitamin D3 capsule during 6 weeks.
- **Placebo** (PLACEBO_COMPARATOR) — Subjects in the placebo arm will receive a daily placebo capsule during 6 weeks.

## Interventions

- **Vitamin D3** (DIETARY_SUPPLEMENT) — A daily 5.000 IU vitamin D3 capsule during 6 weeks.
- **Placebo** (DIETARY_SUPPLEMENT) — A daily placebo capsule during 6 weeks.

## Primary Outcomes

- **Change in Total Cholesterol Levels** _(time frame: Baseline and 6 weeks)_

## Secondary Outcomes

- **Change in Fasting Glucose Levels** _(time frame: Baseline and 6 weeks)_
- **Change in HOMA Index** _(time frame: Baseline and 6 weeks)_
- **Change in Glycated Hemoglobin Levels** _(time frame: Baseline and 6 weeks)_
- **Change in Low-Density Lipoprotein Levels** _(time frame: Baseline and 6 weeks)_
- **Change in High-Density Lipoprotein Levels** _(time frame: Baseline and 6 weeks)_
- **Change in Triglycerides Levels** _(time frame: Baseline and 6 weeks)_
- **Change in C-Reactive Protein Levels** _(time frame: Baseline and 6 weeks)_
- **Change in Vitamin D Levels** _(time frame: Baseline and 6 weeks)_
- **Change in PASI (Psoriasis Area Severity Index)** _(time frame: Baseline and 6 weeks)_

## Locations (1)

- Pontificia Universidad Católica de Chile, Santiago, Santiago Metropolitan, Chile

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.pontificia universidad católica de chile|santiago|santiago metropolitan|chile` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02271971.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02271971*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*